N-benzoylcysteine methyl ester | 5673-89-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzoylcysteine methyl ester
• 英文别名: Methyl 2-benzamido-3-sulfanylpropanoate
• CAS: 5673-89-2
• 化学式: C₁₁H₁₃NO₃S
• 分子量: 239.295
• InChiKey: LNDQVORYPJTVBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  56.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-benzoylcysteine methyl ester 在 正丁基锂 、 碘甲烷 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-benzoylaminoacrylic acid methyl ester
  参考文献：
  名称：

  Easton, Christopher J.; Peters, Steven C., Australian Journal of Chemistry, 1990, vol. 43, # 1, p. 87 - 97

  摘要：

  DOI：

文献信息

• METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
  申请人：Catabasis Pharmacauticals, Iinc.

  公开号：US20150344430A1

  公开（公告）日：2015-12-03

  The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.

  本发明涉及使用脂肪酸衍生物抑制前蛋白酶转化酶亚精氨酸/酶切割酶9 (PCSK9)来调节胆固醇的新方法；以及通过给予有效量的脂肪酸衍生物来治疗或预防代谢性疾病的新方法。本发明还涉及脂肪酸生物活性衍生物及其在治疗代谢性疾病中的应用。
• ANTI-WRINKLE AGENTS
  申请人：Pola Chemical Industries Inc.

  公开号：EP2356979B1

  公开（公告）日：2017-10-25
• EASTON, CHRISTOPHER J.;PETERS, STEVEN C., AUSTRAL. J. CHEM., 43,(1990) N, C. 87-97
  作者：EASTON, CHRISTOPHER J.、PETERS, STEVEN C.

  DOI：——

  日期：——
• [EN] CONTROLLED CHEMICAL RELEASE OF HYDROGEN SULFIDE<br/>[FR] LIBÉRATION CHIMIQUE CONTRÔLÉE DE SULFURE D'HYDROGÈNE
  申请人：UNIV WASHINGTON STATE RES FDN

  公开号：WO2012075242A2

  公开（公告）日：2012-06-07

  Agents of formula: where R1 and R2 vary independently and are acyl, sulfonyl, phosphoryl, alkyl, substituted alkyl, halogen, aryl, arylalkyl, substituted aryl, heteroaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, heterocycle, or heteroatoms; and R3 is H or a member of a ring structure which includes R2, are provided; as are agents of formula: where R1, R2 and R3 vary independently and: R1 = OH, OR', NHR', NR'R" (with R' R" = alkyl, aryl, heteroaryl, etc); R2 = acyl, alkyl, aryl, sulfonyl, etc; R3 = alkyl, aryl, substituted aryl, heteroaryl, etc; and R4 and R5 are (independently) H, methyl or alkyl, substituted alkyl, aryl, substituted aryl, etc. Methods of using the agents to treat e.g. cardiovascular disease, stroke, shock, injuries caused by hypoxia, male erectile dysfunction, and Alzheimer's are provided.
• Easton, Christopher J.; Peters, Steven C., Australian Journal of Chemistry, 1990, vol. 43, # 1, p. 87 - 97
  作者：Easton, Christopher J.、Peters, Steven C.

  DOI：——

  日期：——